Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
Joon H. Uhm(Mayo Clinic), Kurt A. Jaeckle(Jacksonville College), Patrick J. Flynn(American Society of Clinical Oncology), Wenting Wu(Wenzhou Institute of Industrial Science), Jan C. Buckner(McGill University), Shaker R. Dakhill(Wichita Clinic), Caterina Giannini(Mayo Clinic), Karla V. Ballman(National Cancer Institute), Robert J. Behrens(Iowa Oncology Research Association), John C. Krauss(University of Michigan), C. David James(Northwestern University), Bernd W. Scheithauer(Mayo Clinic), Paul Schaefer(Community Hospital)
Cited by 186
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k